Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
This article analyzes Supernus Pharmaceuticals, Inc.'s recent stock performance as it reached a new 52-week high. It will likely discuss factors contributing to this surge and whether the stock has further potential for growth. Investors would be interested in the analysis of its valuation and market position.
Understanding the Setup: (SUPN) and Scalable Risk
This article analyzes Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), identifying a strong near-term sentiment with a long-term positive bias, following a mid-channel oscillation pattern. It highlights an exceptional 39.6:1 risk-reward setup targeting an 11.2% gain versus 0.3% risk. The article outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles using AI-generated signals and risk management parameters.
Hennion & Walsh Asset Management Inc. Has $4.01 Million Position in Supernus Pharmaceuticals, Inc. $SUPN
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 20.7% in Q4, holding 80,651 shares valued at $4.01 million. This comes as company insiders have sold a substantial amount of stock, with CEO Jack A. Khattar selling shares worth $1.76 million in March. Analysts currently have a mixed view on SUPN, with a consensus "Hold" rating and an average target price of $62.17 against its current trading price of around $49.35.
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 45.6% in the third quarter, while several other institutional investors increased their positions. Notably, insiders, including the company's director and CEO, have sold a substantial amount of shares recently. Analysts currently have a mixed outlook on SUPN, with a consensus "Hold" rating and a price target of $62.17.
Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN
Tudor Investment Corp ET AL has made a new investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), purchasing 30,015 shares valued at approximately $1.43 million, representing 0.05% of the company. Despite this new institutional interest, insiders have been net sellers, with the CEO and other insiders selling a significant number of shares. Analyst sentiment towards SUPN is mixed, with an average "Hold" rating and an average price target of $62.17.
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
A Supernus Pharmaceuticals executive, Padmanabh P. Bhatt, sold 107,250 shares of common stock worth approximately $5.4 million between March 16-18, 2026. This sale, executed under a prearranged Rule 10b5-1 plan, occurred during a period where Supernus's stock surged 53% over the past year. Despite the large insider sale, the company continues to expand its CNS portfolio, although profitability remains uneven due to higher operating costs.
Vanguard disaggregates holdings after internal realignment (SUPN)
Vanguard has filed an amended Schedule 13G/A for Supernus Pharmaceuticals Inc. (SUPN), reporting 0 shares beneficially owned and 0% ownership after an internal realignment that took effect on January 12, 2026. This realignment, guided by SEC Release No. 34-39538, caused Vanguard's subsidiaries to report their holdings separately, thus disaggregating Vanguard's reported beneficial ownership. The filing, signed by Ashley Grim on March 27, 2026, reflects a reporting change rather than a transaction.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts
Seven analyst firms have issued a consensus "Hold" rating for Supernus Pharmaceuticals (NASDAQ:SUPN), with an average 1-year price target of $62.17. While some analysts have rated the stock as "buy," others have given "sell" or "hold" ratings, reflecting mixed sentiment. Corporate insiders have recently sold a significant amount of shares, though insiders still collectively own 8.80% of the company.
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above 200-Day Moving Average - What's Next?
Supernus Pharmaceuticals (NASDAQ:SUPN) shares have crossed above their 200-day moving average, trading at $50.06 with a 200-day MA of $49.31, suggesting a potential technical breakout. Analyst sentiment is mixed with a "Hold" consensus and an average price target of $62.17, while insiders have been net sellers, divesting 120,881 shares in the last quarter. The company, a specialty pharmaceutical firm focusing on CNS therapies, has a market cap of $2.88 billion.
Insurer Need Not Cover Parkinson's Drug Antitrust Dispute
A Maryland federal judge ruled that an insurer is not obligated to cover a pharmaceutical company in an antitrust lawsuit. The suit accuses the company of suppressing generic versions of its Parkinson's treatment, Apokyn. The article indicates that a full view of the content requires registration.
Jefferies reiterates Supernus Pharmaceuticals stock Buy rating By Investing.com
Jefferies has reiterated a Buy rating and a $65.00 price target for Supernus Pharmaceuticals (NASDAQ:SUPN). The firm noted that Onapgo's weekly scripts are nearing historical levels following a supply resolution in February 2026, with new prescriptions quickly recovering. This positive outlook is supported by strong Q4 2025 revenues, exceeding estimates, and a high gross profit margin, leading to analysts like TD Cowen and Cantor Fitzgerald also maintaining positive ratings and price targets.
SUPN Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for Supernus Pharmaceuticals (SUPN). It details past quarterly results, analyst forecasts for revenue and EPS in 2026/Q1, and the correlation between earnings revisions and stock price movements. The article also includes historical stock performance around earnings reports and a summary of the sentiment from the Q4 2025 earnings call, indicating potential positive stock movement.
The Technical Signals Behind (SUPN) That Institutions Follow
This article provides an analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) based on AI-generated technical signals. It highlights weak near and mid-term sentiment, elevated downside risk, and presents institutional trading strategies including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for SUPN.
SUPN Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Supernus Pharmaceuticals (SUPN), including its Q4 2025 financial results and 2026 guidance. Supernus reported record revenues and earnings for Q4 2025, exceeding expectations, and provided optimistic revenue and earnings projections for the full year 2026. The company's stock, SUPN, notably rebounded after its earnings announcement, rising by 4.7%.
SUPN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Supernus Pharmaceuticals Inc (SUPN). It indicates a 'Sell' technical sentiment based on a proprietary analysis aggregating 14 technical signals, with 8 indicators showing sell and 6 showing buy. Key metrics like MACD, RSI, and various moving averages are detailed, along with support and resistance levels.
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock
Supernus Pharmaceuticals (NASDAQ:SUPN) VP Padmanabh Bhatt recently sold 7,250 shares of company stock for $359,600, reducing his stake by nearly 30%. Despite the sale, which lowered Supernus's stock price, analysts have a mixed view with an average "Hold" rating and a target price of $62.17. The company specializes in CNS therapies with a market cap of $2.84 billion.
Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock
Supernus Pharmaceuticals (NASDAQ:SUPN) VP Padmanabh Bhatt sold 50,000 shares of company stock for $2,514,000, significantly reducing his holdings by 74.58%. The sale, disclosed in an SEC filing, occurred on March 16th and caused the stock to dip about 3% to $49.29 on Wednesday. Analyst sentiment is mixed, with a consensus "Hold" rating and a $62.17 price target, while institutional investors show varying activity.
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity
Padmanabh P. Bhatt, Senior Vice President and Chief Scientific Officer of SUPERNUS PHARMACEUTICALS, INC. (SUPN), exercised employee stock options and sold common stock between March 16 and March 18, 2026. He acquired 107,250 shares through options, with exercise prices ranging from $27.94 to $39.40, and subsequently sold the same number of shares on the open market at weighted average prices between $49.34 and $51.15. These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025, leaving Bhatt with 17,044 directly held shares.
Supernus Pharmaceuticals CEO Sells $1.76M in Stock
Supernus Pharmaceuticals CEO Jack Khattar sold 35,000 shares of the company's stock for $1.76 million, reducing his stake by 3.52%. This transaction, coupled with mixed analyst coverage (four Buy, one Hold, two Sell ratings), indicates uncertainty regarding the stock's future performance and valuation. Investors are advised to monitor the situation closely.
SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise
Supernus Pharmaceuticals (NASDAQ: SUPN) filed a Form 144 notice for the proposed resale of 57,250 shares of common stock, stemming from an exercise of stock options on March 17, 2026. Morgan Stanley Smith Barney LLC is identified as the broker-dealer. The filing also notes a previous 10b5-1 sale of 50,000 shares by Padmanabh P. Bhatt on March 16, 2026.
SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Supernus Pharmaceuticals Inc (SUPN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Qelbree is identified as SUPN's primary revenue driver, while the company's gross margin is strong, its net margin and ROE are negative. The analysis also benchmarks SUPN's performance against industry peers like TARS and IDYA.
Aristotle Capital Boston LLC Sells 503,122 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Aristotle Capital Boston LLC significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 62.2% in the third quarter, selling over 500,000 shares. Following this sale, the fund now holds 305,273 shares, representing about 0.53% of the company. Despite varied institutional investment activity and some insider selling, analysts have a mixed view on SUPN, with an average rating of "Hold" and a target price of $62.17.
[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing
This article details an SEC Form 144 filing by Supernus Pharmaceuticals, Inc. (SUPN) regarding a proposed sale of 50,000 shares of common stock with an aggregate market value of $2,495,500. The shares were acquired on March 16, 2026, through the exercise of stock options, and the sale is planned for the same date on NASDAQ through Morgan Stanley Smith Barney LLC. The filing also notes that the filer does not know of any material adverse, undisclosed information about the issuer.
Director at Supernus (NASDAQ: SUPN) sells 5,369 shares
Frederick M. Hudson, a director at Supernus Pharmaceuticals (NASDAQ: SUPN), reported an open-market sale of 5,369 shares of common stock on March 12, 2026. The shares were sold at a weighted average price of $50.61 per share, with trades executed between $50.45 and $50.82. Following this transaction, Mr. Hudson directly holds 60,413 shares of the company.
Insider Sell Alert: Frederick Hudson Sells Shares of Supernus Pharmaceuticals Inc (SUPN)
Frederick Hudson, a Director at Supernus Pharmaceuticals Inc, sold 5,369 shares of the company on March 12, 2026, bringing his total ownership to 60,413 shares. Over the past year, Hudson has sold 12,826 shares with no purchases, contributing to a total of 30 insider sells against zero insider buys for Supernus Pharmaceuticals Inc. The stock was trading at $50.61 on the day of the sale, significantly overvalued compared to its GF Value estimate of $38.14.
Supernus (NASDAQ: SUPN) CEO-linked KBT Trust sells 35,000 shares under 10b5-1 plan
Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), reported that the KBT Trust, associated with him, sold 35,000 shares of common stock on March 13, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices between $50 and $52 per share. Additionally, 12,500 shares were transferred from the KBT Trust to Khattar directly without consideration, adjusting his direct and indirect holdings.
SUPN SEC Filings - Supernus Pharma 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Supernus Pharma SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It details Supernus's focus on CNS diseases, recent corporate transactions like the acquisition of Sage Therapeutics, and various insider trading activities by executives like Jack A. Khattar. The platform also offers AI-powered tools for quick summaries of these regulatory documents.
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns
Supernus Pharmaceuticals (SUPN) has shown mixed returns recently, with short-term declines but positive long-term gains over one, three, and five years. Despite some recent pullback, the stock is currently trading around $49.91 and is considered "21% Undervalued" by a popular narrative, with a fair value estimate of $63.17, driven by expanding patient pools for core products and strategic market positioning. Investors are advised to consider both the optimism around potential growth and pressure points like reliance on a few key drugs and rising operational costs.
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns
Supernus Pharmaceuticals (SUPN) is currently trading at $49.91, showing recent short-term declines but positive long-term returns. The company is considered 21% undervalued with a narrative fair value estimate of $63.17, driven by expanding product market share and commercial infrastructure. Despite promising growth, the valuation faces risks due to reliance on a few key drugs and rising operational costs.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
This article analyzes Supernus Pharmaceuticals (SUPN) after it reached a new 52-week high, raising questions about whether its stock can continue to climb. It highlights the company's strong price performance, favorable estimates revision for earnings, and Zacks Rank #1 (Strong Buy) status as indicators of potential further growth. The analysis also covers SUPN's industry rank and sector performance.
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns
Supernus Pharmaceuticals (SUPN) has shown mixed returns recently, with short-term pullbacks against strong long-term gains. Trading around $49.91, a narrative fair value estimate places the stock at $63.17, suggesting it is 21% undervalued based on expected growth in core products and market share capture in CNS disorders. Investors should consider both the potential upside and challenges like reliance on key drugs and rising operating costs.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
This article looks at Supernus Pharmaceuticals (SUPN) which recently hit a new 52-week high. It will likely discuss factors contributing to this performance and analyze if the stock has further upside potential. Investors will be interested in understanding the company's valuation and growth prospects.
[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing
This article provides details of a Form 144 SEC filing by Supernus Pharmaceuticals, Inc. (SUPN). The filing indicates a proposed sale of 35,000 shares of common stock with an aggregate market value of $1,766,100, acquired on December 22, 2005. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ.
Supernus Pharmaceuticals Stock Review: Valuation & Business Quality Concerns - News and Statistics
Despite Supernus Pharmaceuticals shares outperforming the S&P 500 recently, an analysis highlights concerns regarding its business quality and valuation. The company's sales growth over five years is considered mediocre for the healthcare sector, and its relatively small size ($719 million revenue) may pose challenges in a complex, regulated industry. Furthermore, a declining free cash flow margin and a forward price-to-earnings multiple of 22.8 suggest that the stock's current valuation already reflects positive expectations, potentially limiting future investment opportunities.
Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc.
Jefferies Financial Group Inc. significantly increased its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 62.0% in Q3, acquiring an additional 32,979 shares to own a total of 86,179 shares valued at $4.12 million. Despite this institutional buying, company insiders have been net sellers, offloading 43,972 shares worth approximately $2.27 million over the past three months. Analyst sentiment remains mixed, with a consensus "Hold" rating and a target price of $62.17.
Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN
Dimensional Fund Advisors LP reduced its stake in Supernus Pharmaceuticals by 0.6% in Q3, now holding 3,001,941 shares valued at $143.46 million. Insider selling has also been noted, with Georges Gemayel selling 8,787 shares and total insider sales reaching $2.27 million over the past 90 days. Wall Street analysts currently hold a consensus "Hold" rating for the stock, with an average price target of $62.17.
Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones
This article provides a precision trading analysis for Supernus Pharmaceuticals Inc. (SUPN), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 32.1:1 risk-reward short setup and offers institutional trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis is based on AI models and multi-timeframe signal analysis, providing support and resistance levels across different time horizons.
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN
American Century Companies Inc. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ: SUPN) during Q3, selling 44.4% of its shares. Despite this, other institutional investors increased their holdings, and company insiders have been net sellers. The stock is currently trading near $53.87, with analysts holding a "Hold" consensus rating and a target price of $62.17.
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update
Supernus Pharmaceuticals (SUPN) has generated fresh interest after strong Q4 2025 results and new 2026 guidance, which includes higher revenue expectations. Despite a significant 67.98% shareholder return over the past year, the stock is considered undervalued with a fair value of $61.33 per share compared to its current price of $53.87. This optimism is driven by expanding patient pools for its core CNS products and a strong commercial infrastructure, though risks like rising costs and product dependence remain.
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant
Supernus Pharmaceuticals' Senior Vice-President & CFO, Timothy C. Dec, acquired 3,000 performance share units at no exercise price. These units were originally awarded on February 22, 2024, with a portion vesting upon the achievement of individual performance objectives established on June 24, 2024. This transaction, revealed in an SEC Form 4 filing, reflects equity compensation tied to performance rather than an open market purchase.
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units
Supernus Pharmaceuticals (SUPN) Senior Vice President and Chief Technology Operations Officer Frank Mottola was awarded 3,750 Performance Share Units, as reported in a recent SEC Form 4 filing. This equity award, granted at $0.00 per unit, vested after individual performance objectives established in June 2023 were achieved. Mottola now directly holds 3,750 of these derivative securities.
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units
Supernus Pharmaceuticals CEO Jack A. Khattar was awarded 38,640 Performance Share Units with a price of $0.00 per unit, as reported in a recent SEC Form 4 filing. The grant occurred on February 22, 2024, and a portion of these units will vest upon the achievement of individual performance objectives established on June 24, 2024. This transaction reflects a performance-based equity award rather than a market purchase, aligning the executive's compensation with specific company and individual performance goals.
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge?
Supernus Pharmaceuticals (SUPN) has seen a 74% stock price surge over the last year, prompting questions about its current valuation. According to a Discounted Cash Flow (DCF) analysis, the stock appears significantly undervalued by 72.3%, suggesting a fair value of $198.54 compared to its current price of approximately $55.09. Additionally, its Price/Sales ratio of 4.40x is below its estimated "Fair Ratio" of 5.87x, further indicating undervaluation even after its recent strong performance.
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge?
Supernus Pharmaceuticals (SUPN) has seen a significant 74% surge over the past year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is currently undervalued by 72.3%, with an estimated intrinsic value of $198.54 per share against a current price of $55.09. Additionally, its Price/Sales (P/S) ratio of 4.40x is close to the industry average and below its estimated "Fair Ratio" of 5.87x, further indicating undervaluation based on this metric.
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS
Supernus Pharmaceuticals reported total revenues of $718.95 million for 2025, a 9% increase from the prior year, despite a net loss of $(38.55) million, or $(0.68) per share, largely due to acquisition-related charges and amortization from the Sage acquisition. The company highlighted strong performance in products like Qelbree and GOCOVRI, balancing out generic erosion of other drugs, and outlined ongoing R&D and pipeline developments.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts
Seven brokerages have issued a consensus "Hold" rating for Supernus Pharmaceuticals (NASDAQ:SUPN), with an average 12-month price target of $62.17. Recent insider selling includes SVP Frank Mottola selling 20,000 shares, contributing to a total of 25,185 insider shares sold in the last 90 days. The stock's performance shows varying analyst recommendations and institutional trading activity, alongside a negative P/E ratio and a market capitalization of $3.14 billion.
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook
Supernus Pharmaceuticals (SUPN) saw a 7.6% increase after reporting record 2025 revenue of US$718.95 million, but also a net loss of US$38.55 million for the year. The company provided a cautious 2026 outlook, forecasting operating earnings of US$0–US$30 million on revenues of US$840–US$870 million, driven by new CNS products and the Sage Therapeutics acquisition, but also impacted by rising costs. Investors are weighing strong revenue guidance against potential profitability challenges due to increased SG&A and R&D expenses.
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook
Supernus Pharmaceuticals reported record 2025 revenues, but also a net loss for the year and a cautious 2026 outlook with operating earnings projected between US$0 and US$30 million, despite an expected revenue increase to US$840–US$870 million. The company's immediate focus is on executing ONAPGO's launch and integrating Sage, while managing rising costs that could impact profitability. Despite the record sales, investors are advised to consider the potential for higher SG&A and R&D expenses to pressure GAAP profitability.
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions
Supernus Pharmaceuticals reported record revenues in 2025, driven by the integration of Sage Therapeutics and the launch of new CNS drugs, ONAPGO and ZURZUVAE. The company expanded into new therapeutic areas, and despite a current net income loss, the stock is flagged as undervalued by Simply Wall St, trading 72.4% below its fair value estimate. Investors are advised to monitor the adoption of new products and manage supply constraints reflected in future company updates.
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Supernus Pharmaceuticals (SUPN) by 2.6% in the third quarter, selling over 160,000 shares but still owning approximately 10.78% of the company. The stock opened at $54.73, has a market cap of $3.14 billion, and has received mixed analyst ratings, with a consensus "Hold." Company insiders have also sold a notable number of shares in recent months.
